
Attovia Building Immune-Mediated Disease Pipeline with $90M Series C
Attovia Therapeutics CEO Tao Fu Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates through clinical proof- …